| Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen (NCT04891237) | Inmunotek S.L. | 2021-06-14 |
| Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. (NCT04898283) | Inmunotek S.L. | 2021-05-31 |
| Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites (NCT04435990) | Inmunotek S.L. | 2020-10-06 |
| Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber (NCT04583202) | Alyatec | 2020-02-24 |
| Intervention in Chronic Pediatric Patients and Their Families. (NCT04476433) | University of Valencia | 2019-02-04 |
| Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma (NCT03821077) | Roxall Medicina España S.A | 2018-08-30 |
| Red Maple Trials Cat Allergen Natural Exposure Chamber Validation in Cat-allergic Subjects (NCT03414801) | Red Maple Trials Inc. | 2018-02-06 |
| Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice (NCT02844842) | Roxall Medicina España S.A | 2016-11-23 |
| Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy (NCT02661854) | Inmunotek S.L. | 2016-06-21 |
| A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea (NCT02849210) | Roxall Medicina España S.A | 2015-09-01 |
| A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica (NCT02477917) | Roxall Medicina España S.A | 2015-05-01 |
| Ragweed-SPIRE Follow-On Study (NCT02396680) | Circassia Limited | 2015-04-01 |
| Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma (NCT02340130) | Laboratorios Leti, S.L. | 2014-09-01 |
| Phase II HDM-SPIRE Safety and Efficacy Study (NCT02150343) | Circassia Limited | 2014-09-01 |
| Grass Observational Study (NCT02075138) | Circassia Limited | 2014-04-01 |
| ToleroMune Grass Follow on Study (NCT02292875) | Circassia Limited | 2014-04-01 |
| ToleroMune House Dust Mite (HDM) Tolerability Study (NCT01949441) | Circassia Limited | 2013-09-01 |
| House Dust Mite Observational Study (NCT01949428) | Circassia Limited | 2013-09-01 |
| ToleroMune House Dust Mite Follow on Study (NCT01923792) | Circassia Limited | 2013-09-01 |
| An Optional Investigation of Biomarkers of Efficacy (NCT01949415) | Circassia Limited | 2013-09-01 |
| Paediatric Safety Study in Cat-PAD (NCT01921257) | Circassia Limited | 2013-08-01 |
| ToleroMune Grass Follow on Study (NCT01923779) | Circassia Limited | 2013-05-01 |
| Ocular Allergy Treatment Practical Impact Trial (NCT01808768) | Starx Research Center, LLC | 2013-04-01 |
| Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml). (NCT01734265) | Laboratorios Leti, S.L. | 2012-11-01 |
| Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy (NCT01720251) | Anergis | 2012-10-01 |
| Phase III Cat-PAD Study (NCT01620762) | Circassia Limited | 2012-10-01 |
| Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma (NCT01591343) | Laboratorios Leti, S.L. | 2012-06-01 |
| An Optional Two Year Follow Up Study to Study CP005A (NCT01604018) | Circassia Limited | 2012-02-01 |
| ToleroMune Ragweed Follow up Study (NCT01448603) | Circassia Limited | 2011-10-01 |
| ToleroMune Grass Exposure Unit Study (NCT01385800) | Circassia Limited | 2011-08-01 |
| Cat-PAD Follow on Study (NCT01272323) | Circassia Limited | 2011-02-01 |
| Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) (NCT00978029) | ALK-Abelló A/S | 2009-11-01 |
| 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma (NCT01353755) | Allergopharma GmbH & Co. KG | 2009-10-01 |
| Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis (NCT01013259) | Charite University, Berlin, Germany | 2009-02-01 |
| Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy (NCT00800332) | Cytos Biotechnology AG | 2008-11-01 |
| Open Label Safety Study of a Birch Pollen Allergen Extract (NCT00818181) | Allergopharma GmbH & Co. KG | 2008-06-01 |
| Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma (NCT00671268) | Allergopharma GmbH & Co. KG | 2008-03-01 |
| Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (NCT00550550) | ALK-Abelló A/S | 2007-11-01 |
| Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (NCT00562159) | ALK-Abelló A/S | 2007-11-01 |
| Multicenter Trial of Immunotherapy With House Dust Mite Allergoid (NCT00540631) | Allergopharma GmbH & Co. KG | 2007-10-01 |
| Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT) (NCT00537342) | Laboratorios Leti, S.L. | 2007-10-01 |
| PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) (NCT00574210) | Faes Farma, S.A. | 2007-10-01 |
| Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration (NCT00457444) | University of Zurich | 2005-12-01 |